NCT04528927

Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia

Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Abderrahmane Mami Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study

Detailed description

Arm 1: * Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days * Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days * Usual standard treatment Arm 2: * HCQ: 600 mg on the 1st day as a starting dose then 200 mg \* 2 / D for 9 days * Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days * Zinc: 220 mg per day for 10 days * Usual standard treatment Arm 3: * Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days * Doxycycline: 200 mg per day for 10 days. * Usual standard treatment

Conditions

• COVID 19
• Patients Hospitalized

Interventions

Type	Name	Description
DRUG	HCQ	600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
DRUG	Azithromycin	500 mg (1st day) then 250 mg / D for 4 days
DRUG	Doxycycline	200 mg per day for 10 days
DIETARY_SUPPLEMENT	Zinc	220 mg per day for 10 days

Timeline

• Start date: 2020-05-15
• Primary completion: 2020-07-15
• Completion: 2020-07-15
• First posted: 2020-08-27
• Last updated: 2020-08-27

Locations

1 site across 1 country: Tunisia